These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9180827)

  • 1. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression.
    Bouwer C; Stein DJ
    S Afr Med J; 1997 Apr; 87(4 Suppl):534-7, 540. PubMed ID: 9180827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression.
    Fischer P; Tauscher J; Küfferle B; Kasper S
    Int Clin Psychopharmacol; 1998 Mar; 13(2):83-6. PubMed ID: 9669189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
    Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
    J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.
    Landén M; Björling G; Agren H; Fahlén T
    J Clin Psychiatry; 1998 Dec; 59(12):664-8. PubMed ID: 9921700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.
    Joffe RT; Schuller DR
    J Clin Psychiatry; 1993 Jul; 54(7):269-71. PubMed ID: 8335654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buspirone augmentation of antidepressant therapy.
    Dimitriou EC; Dimitriou CE
    J Clin Psychopharmacol; 1998 Dec; 18(6):465-9. PubMed ID: 9864079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approaches to the treatment of refractory depression.
    Fava M
    J Clin Psychiatry; 2000; 61 Suppl 1():26-32. PubMed ID: 10703760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication augmentation after the failure of SSRIs for depression.
    Trivedi MH; Fava M; Wisniewski SR; Thase ME; Quitkin F; Warden D; Ritz L; Nierenberg AA; Lebowitz BD; Biggs MM; Luther JF; Shores-Wilson K; Rush AJ;
    N Engl J Med; 2006 Mar; 354(12):1243-52. PubMed ID: 16554526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible augmentation of antidepressant response by buspirone.
    Jacobsen FM
    J Clin Psychiatry; 1991 May; 52(5):217-20. PubMed ID: 2033029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anxiolytic antidepressant augmentation.
    Sussman N
    J Clin Psychiatry; 1998; 59 Suppl 5():42-8; discussion 49-50. PubMed ID: 9635547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response.
    Blier P; Bergeron R; de Montigny C
    Neuropsychopharmacology; 1997 May; 16(5):333-8. PubMed ID: 9109104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lithium augmentation of antidepressants in treatment-refractory depression.
    Heit S; Nemeroff CB
    J Clin Psychiatry; 1998; 59 Suppl 6():28-33; discussion 34. PubMed ID: 9674934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?
    Gaynes BN; Farley JF; Dusetzina SB; Ellis AR; Hansen RA; Miller WC; Stürmer T
    Depress Anxiety; 2011 Nov; 28(11):989-98. PubMed ID: 21898717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation strategies in depression 2000.
    Nelson JC
    J Clin Psychiatry; 2000; 61 Suppl 2():13-9. PubMed ID: 10714619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone.
    Onder E; Tural U
    J Affect Disord; 2003 Sep; 76(1-3):223-7. PubMed ID: 12943952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation strategies: focus on anxiolytics.
    Joffe RT; Levitt AJ; Sokolov ST
    J Clin Psychiatry; 1996; 57 Suppl 7():25-31; discussion 32-3. PubMed ID: 8690693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming treatment resistance in depression.
    Nelson JC
    J Clin Psychiatry; 1998; 59 Suppl 16():13-9; discussion 40-2. PubMed ID: 9796861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation with buspirone: a review.
    Harvey KV; Balon R
    Ann Clin Psychiatry; 1995 Sep; 7(3):143-7. PubMed ID: 8646275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the use of augmentation therapy for the treatment of resistant depression: implications for the clinician.
    Schweitzer I; Tuckwell V; Johnson G
    Aust N Z J Psychiatry; 1997 Jun; 31(3):340-52. PubMed ID: 9226079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.